FY2027 Earnings Estimate for Tandem Diabetes Care, Inc. Issued By Leerink Partnrs (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Analysts at Leerink Partnrs issued their FY2027 EPS estimates for Tandem Diabetes Care in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky expects that the medical device company will post earnings of ($0.01) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2028 earnings at $0.27 EPS.

TNDM has been the subject of a number of other research reports. Wells Fargo & Company upped their target price on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group began coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective for the company. Robert W. Baird lifted their target price on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Royal Bank of Canada started coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price target for the company. Finally, Barclays lifted their price objective on Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.13.

Tandem Diabetes Care Stock Performance

TNDM opened at $37.50 on Thursday. The stock has a 50-day moving average of $42.06 and a 200-day moving average of $41.89. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $53.69. The company has a market cap of $2.45 billion, a PE ratio of -17.94 and a beta of 1.33.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The firm had revenue of $221.90 million during the quarter, compared to analysts’ expectations of $205.63 million. During the same period in the prior year, the company posted ($0.30) earnings per share. Tandem Diabetes Care’s revenue for the quarter was up 13.3% on a year-over-year basis.

Institutional Investors Weigh In On Tandem Diabetes Care

Hedge funds have recently made changes to their positions in the company. ORG Wealth Partners LLC bought a new stake in Tandem Diabetes Care during the third quarter worth about $30,000. ORG Partners LLC bought a new stake in Tandem Diabetes Care during the 2nd quarter worth approximately $31,000. Headlands Technologies LLC bought a new stake in Tandem Diabetes Care during the 1st quarter worth approximately $35,000. MCF Advisors LLC increased its holdings in Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in Tandem Diabetes Care in the 2nd quarter valued at $86,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.